losartan has been researched along with Retinal Neovascularization in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J | 1 |
| Dong, XG | 1 |
| Lonchampt, M | 1 |
| Pennel, L | 1 |
| Duhault, J | 1 |
2 other studies available for losartan and Retinal Neovascularization
| Article | Year |
|---|---|
[Experimental study of (Pro)renin receptor siRNA inhibiting retinal neovascularization].
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Movement; Cell Proliferation; Disease Models, | 2011 |
Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |